Outset Medical, Inc. - Common Stock, par value $0.001 per share (OM)

CUSIP: 690145107

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
-2,522,924
Put/Call ratio
51%
SEC-reported price per share
$2.22
Indexed holders
109
Value change
-$20,061,860
Number of buys
42
Open additional details 1 more signal available
Number of sells
74
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
18,527,213

Security key

690145107

Report period

Q1 2024

Indexed institutions

109

Top holders

10

Ownership snapshot

Top reported holders of OM - Outset Medical, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
JPMORGAN CHASE & CO
Disclosed value leader
JPMORGAN CHASE & CO
Comparable rows
0/15
Latest evidence
31 Dec 2023
13F Highest disclosed value: $26,840,086 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

JPMORGAN CHASE & CO has the largest disclosed position value at $26.84M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens JPMORGAN CHASE & CO's linked filing trail.
Disclosed position value Top 5
JPMORGAN CHASE & CO $26.84M
VANGUARD GROUP INC $21.32M
MORGAN STANLEY $20.93M
BlackRock Finance, Inc. $20.53M
T. Rowe Price Investment Manageme... $17.13M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
JPMORGAN CHASE & CO
13F
Company
13F
—
denominator unverified
$26,840,086
4,961,199 shares
— 31 Dec 2023
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$21,322,796
3,941,367 shares
— 31 Dec 2023
MORGAN STANLEY
13F
Company
13F
—
denominator unverified
$20,926,229
3,868,064 shares
— 31 Dec 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$20,533,218
3,795,419 shares
— 31 Dec 2023
T. Rowe Price Investment Management, Inc.
13F
Company
13F
—
denominator unverified
$17,133,000
3,166,747 shares
— 31 Dec 2023
AMERIPRISE FINANCIAL INC
13F
Company
13F
—
denominator unverified
$16,135,271
2,982,490 shares
— 31 Dec 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
109
Shares
50,439,872
Indexed holders
109
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 indexed holders
137
Q1 2024 indexed holders
109
Indexed holder difference
-28
Investor Q4 2023 Shares Q1 2024 Shares Share Diff Share Chg % Q4 2023 value Q1 2024 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .